2. Search Result
Search Result
Results for "

L-dopa

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

4

Peptides

16

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0304
    L-DOPA
    Maximum Cited Publications
    35 Publications Verification

    Levodopa; 3,4-Dihydroxyphenylalanine

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA
  • HY-B0404A
    Benserazide hydrochloride
    5+ Cited Publications

    Ro 4-4602 hydrochloride

    		 Pyruvate Kinase Neurological Disease Cancer
    Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma .
    Benserazide hydrochloride
  • HY-15257
    Mavoglurant
    4 Publications Verification

    AFQ056

    		 mGluR Neurological Disease
    Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mavoglurant
  • HY-N0304R
    L-DOPA (Standard)
    1 Publications Verification

    Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)

    		 Reference Standards Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA (Standard)
  • HY-162666
    TMEM175 modulator 1

    		Potassium Channel Neurological Disease
    TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia .
    TMEM175 modulator 1
  • HY-121275
    Benserazide
    5+ Cited Publications

    Ro 4-4602

    		 Pyruvate Kinase Neurological Disease Cancer
    Benserazide is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide is also a PKM2 inhibitor. Benserazide directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide can be used for the study of Parkinson's disease and melanoma .
    Benserazide
  • HY-N0304A
    L-DOPA sodium
    Maximum Cited Publications
    35 Publications Verification

    Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .
    L-DOPA sodium
  • HY-113468A
    3-O-Methyldopa
    1 Publications Verification

    3-Methoxy-L-tyrosine; 3-O-Methyl-L-dopa

    		 Drug Derivative Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa
  • HY-P1335
    CTAP
    2 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
    CTAP
  • HY-N2278
    Kushenol A
    4 Publications Verification

    Leachianone E

    		 Tyrosinase Glycosidase Cancer
    Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC50 and Kivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC50: 45 μM; Ki: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .
    Kushenol A
  • HY-116016
    Etilevodopa

    L-dopa ethyl ester; Levodopa ethyl ester

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa
  • HY-132392S
    L-DOPA-2,5,6-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain .
    L-DOPA-2,5,6-d3
  • HY-113468AS
    3-O-Methyldopa-d3

    3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-dopa-d3

    		 Isotope-Labeled Compounds Drug Metabolite Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa-d3
  • HY-113357
    m-Coumaric acid

    		Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid
  • HY-B0927
    Hydrastine

    (-)-β-Hydrastine; (1R,9S)-β-Hydrastine

    		 Tyrosine Hydroxylase Dopamine Receptor OAT Neurological Disease
    Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine) is a selective competitive inhibitor of tyrosine hydroxylase (TH), inhibiting dopamine biosynthesis (IC50=20.7 μM, PC12 cells). Hydrastine also inhibits the organic cation transporter OCT1 (IC50=6.6 μM). Hydrastine may cause neuronal toxicity through mitochondrial dysfunction rather than oxidative stress damage, and can aggravate cell apoptosis when combined with L-DOPA. Hydrastine can be used to study Parkinson's disease-related dopaminergic neuronal damage .
    Hydrastine
  • HY-N0304S
    L-DOPA-d6

    Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-d6
  • HY-141647
    18F-Labeled L-dopa precursor

    		Dopamine Receptor Drug Intermediate Others
    18F-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa .
    18F-Labeled L-dopa precursor
  • HY-N0304S2
    L-DOPA-13C
    1 Publications Verification

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA- 13C is the 13C labeled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-13C
  • HY-106405
    Nebicapone

    BIA 3-202

    		 COMT Metabolic Disease
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
    Nebicapone
  • HY-W152604
    Cyclo(glycyl-L-leucyl)

    Cyclo(leu-gly)

    		 Dopamine Receptor Neurological Disease
    Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .
    Cyclo(glycyl-L-leucyl)
  • HY-W037976
    Tyrosinase-IN-22

    5-Chloro-2-mercaptobenzimidazole

    		 Reactive Oxygen Species (ROS) Tyrosinase Cancer
    Tyrosinase-IN-22 (compound 4) is an inhibitor of tyrosinase substrates (L-tyrosine and L-dopa) with IC50s of 60 nM and 30 nM, respectively. Tyrosinase-IN-22 also shows potent antioxidant and anti-melanogenic properties, thus can be used for relevant researches .
    Tyrosinase-IN-22
  • HY-113468AR
    3-O-Methyldopa (Standard)

    3-Methoxy-L-tyrosine (Standard); 3-O-Methyl-L-dopa (Standard)

    		 Drug Derivative Interleukin Related Reference Standards Neurological Disease Inflammation/Immunology
    3-O-Methyldopa (Standard) is the analytical standard of 3-O-Methyldopa. This product is intended for research and analytical applications. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .
    3-O-Methyldopa (Standard)
  • HY-P1335A
    CTAP TFA
    2 Publications Verification

    		 Opioid Receptor Neurological Disease
    CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
    CTAP TFA
  • HY-116016A
    Etilevodopa hydrochloride

    L-dopa ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa hydrochloride
  • HY-N0304S1
    L-DOPA-13C6

    Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA- 13C6 is the 13C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-13C6
  • HY-W012264
    3-O-Methyldopa monohydrate

    3-Methoxy-L-tyrosine monohydrate; 3-O-Methyl-L-dopa monohydrate

    		 COMT Neurological Disease
    3-O-Methyldopa monohydrate (3-Methoxy-L-tyrosine monohydrate) is a significant metabolite of L-DOPA produced through the action of catechol O-methyltransferase (COMT). Unlike its precursor, 3-O-Methyldopa does not serve as a substrate or inhibitor of L-amino acid decarboxylase activity. Additionally, the inhibition of COMT can amplify the anti-Parkinson effects of L-DOPA.
    3-O-Methyldopa monohydrate
  • HY-116750
    6-Hydroxykaempferol

    		Tyrosinase Others
    6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC50 value of 124 μM. 6-Hydroxykaempferol has a Ki value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme .
    6-Hydroxykaempferol
  • HY-P2825
    Tyrosine decarboxylase, Microorganism

    TDC; TyrDC

    		 Endogenous Metabolite Others
    Tyrosine decarboxylase, Microorganism (TDC) is a tyrosine decarboxylase produced by microorganisms. Tyrosine decarboxylase is a PLP-dependent enzyme that catalyzes the decarboxylation of L-tyrosine, L-phenylalanine, and L-dopa to produce tyramine, 2-phenethylamine, and dopamine, respectively. Tyrosine decarboxylase mediates acid stress resistance, maintains intracellular pH homeostasis, and generates proton motive force .
    Tyrosine decarboxylase, Microorganism
  • HY-B0404AR
    Benserazide hydrochloride (Standard)

    Ro 4-4602 hydrochloride (Standard)

    		 Reference Standards Pyruvate Kinase Neurological Disease Cancer
    Benserazide hydrochloride (Standard) (Serazide (Standard)) is the analytical standard of Benserazide hydrochloride (HY-B0404A). This product is intended for research and analytical applications. Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma .
    Benserazide hydrochloride (Standard)
  • HY-149207
    Tyrosinase-IN-11

    		Tyrosinase Metabolic Disease
    Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC50s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research .
    Tyrosinase-IN-11
  • HY-B0404AS
    Benserazide-d3 hydrochloride

    Ro 4-4602-d3 hydrochloride

    		 Isotope-Labeled Compounds Pyruvate Kinase Neurological Disease Cancer
    Benserazide-d3 (hydrochloride) is the deuterium labeled Benserazide hydrochloride (HY-B0404A). Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma .
    Benserazide-d3 hydrochloride
  • HY-113357R
    m-Coumaric acid (Standard)

    		Reference Standards Endogenous Metabolite Neurological Disease Inflammation/Immunology
    m-Coumaric acid (Standard) is the analytical standard of m-Coumaric acid. This product is intended for research and analytical applications. m-Coumaric acid is a polyphenol metabolite from caffeic acid, formed by the gut microflora and the amount in human biofluids is diet-dependant. m-Coumaric acid is a BBB-penetrant metabolite of chlorogenic acid. m-Coumaric acid stimulates the cerebral nerves in vitro. m-Coumaric acid can evoke neurite outgrowth in hippocampal neuronal cells. m-Coumaric acid can promote neuronal differentiation. m-Coumaric acid increases spontaneous locomotor activity in mice by acting on the central nervous system. m-Coumaric acid inhibits the oxidation of L-dopa by epidermis tyrosinase. m-Coumaric acid attenuates non-catalytic protein glycosylation in retinas of diabetic rats .
    m-Coumaric acid (Standard)
  • HY-116016AR
    Etilevodopa hydrochloride (Standard)

    L-dopa ethyl ester hydrochloride (Standard); Levodopa ethyl ester hydrochloride (Standard)

    		 Reference Standards Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (hydrochloride) (Standard) is the analytical standard of Etilevodopa (hydrochloride). This product is intended for research and analytical applications. Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
    Etilevodopa hydrochloride (Standard)
  • HY-116016R
    Etilevodopa (Standard)

    L-dopa ethyl ester (Standard); Levodopa ethyl ester (Standard)

    		 Reference Standards Dopamine Receptor Drug Metabolite Neurological Disease
    Chlorbenside (Standard) is the analytical standard of Chlorbenside. This product is intended for research and analytical applications. Chlorbenside is an organochlorine pesticide. Chlorbenside targets organism such as mites and ticks and possesses efficient ovicidal and larvicidal activities .
    Etilevodopa (Standard)
  • HY-176895
    L-Dopa precursor-1

    		Others Cardiovascular Disease
    L-Dopa precursor-1 (Compound 5a) is the precursor of 18F-L-Dopa. L-Dopa precursor-1 serves as a core basis for radioactive labeling precursors, allowing the introduction of non-metallic radioactive elements through radiolabeling reactions. L-Dopa precursor-1 can be used for the study of RDN surgery for refractory hypertension, chronic kidney disease .
    L-Dopa precursor-1
  • HY-W401531S
    (R)-3-O-Methyldopa-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    (R)-3-O-Methyldopa-d3 is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine .
    (R)-3-O-Methyldopa-d3
  • HY-W401531S1
    (R)-3-O-Methyldopa-d3 hydrochloride

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    (R)-3-O-Methyldopa-d3 (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine .
    (R)-3-O-Methyldopa-d3 hydrochloride
  • HY-W046353A
    (E)-2-Methoxycinnamaldehyde

    (E)-o-Methoxycinnamaldehyde

    		 Tyrosinase Neurological Disease
    (E)-2-Methoxycinnamaldehyde ((E)-o-Methoxycinnamaldehyde) is a tyrosinase inhibitor with an IC50 of 0.42 mM for mushroom tyrosinase. (E)-2-Methoxycinnamaldehyde is found in the twigs of Cinnamomum cassia. (E)-2-Methoxycinnamaldehyde can be used for the research of Parkinson's disease .
    (E)-2-Methoxycinnamaldehyde
  • HY-N3237
    Mulberrofuran H

    		Dopamine Receptor Inflammation/Immunology
    Mulberrofuran H is a 2-arylbenzofuran derivative from the cultivated mulberry tree (Morus lhou (ser.) Koidz.). Mulberrofuran H demonstrates potent inhibition against substrates L-tyrosine (IC50=4.45 µM) and L-DOPA (IC50=19.70 µM). Mulberrofuran H also shows potent anti-inflammatory and antioxidative activities .
    Mulberrofuran H
  • HY-175001
    D1/D5 Receptor agonist-1

    		Dopamine Receptor Arrestin Neurological Disease
    D1/D5 Receptor agonist-1 is a highly brain-penetrant and orally active D1/D5 receptor agonist. D1/D5 Receptor agonist-1 maintains considerable efficacy in the cAMP pathway and in β-arrestin recruitment, with EC50s of 3.7 nM (D1R cAMP), 91 nM (D1R β-arrestin), 129 nM (D1R internalization) and a Ki of 111 nM (D1R binding affinity). D1/D5 Receptor agonist-1 inhibits β-arrestin signaling in a rat with L-DOPA (HY-N0304) induced dyskinesias. D1/D5 Receptor agonist-1 can be used for the study of Parkinson’s disease .
    D1/D5 Receptor agonist-1
  • HY-113468AS1
    3-O-Methyldopa-d3 hydrate

    3-Methoxy-L-tyrosine-d3 hydrate; 3-O-Methyl-L-dopa-d3 hydrate

    		 Isotope-Labeled Compounds Drug Metabolite Interleukin Related Neurological Disease Inflammation/Immunology
    3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
    3-O-Methyldopa-d3 hydrate
  • HY-N10950
    Vanicoside E

    		Dopamine Receptor Cancer
    Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and L-DOPA (HY-N0304) with IC50s of 45.23 μM and 189.96 μM, respectively .
    Vanicoside E
  • HY-121939
    6-Hydroxy-L-DOPA

    		Biochemical Assay Reagents Others
    6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .
    6-Hydroxy-L-DOPA
  • HY-113404S1
    L-Dopa-d3

    		Endogenous Metabolite Isotope-Labeled Compounds Others
    L-Dopa-d3 is deuterated labeled DL-Dopa (HY-113404). DL-Dopa is a beta-hydroxylated derivative of phenylalanine.
    L-Dopa-d3
  • HY-121939R
    6-Hydroxy-L-DOPA (Standard)

    		Reference Standards Biochemical Assay Reagents Others
    6-Hydroxy-L-DOPA (Standard) is the analytical standard of 6-Hydroxy-L-DOPA. This product is intended for research and analytical applications. 6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .
    6-Hydroxy-L-DOPA (Standard)
  • HY-175795
    Tyrosinase activator-1

    		Tyrosinase Bacterial Antibiotic Infection
    Tyrosinase activator-1 (Compound 7A) is a Tyrosinase activator. Tyrosinase activator-1 significant antibacterial activity against gram-positive bacteria, such as MRSA, Staphylococcus aureus ATCC653 and Enterococcus faecium with MICs of 12.5-20  μM. Tyrosinase activator-1 activates tyrosinase by competitively occupying the binding site of L-DOPA on the surface of tyrosinase without interfering with the substrate binding at the active center. Tyrosinase activator-1 can be used for bacterial infections and antibiotics development research .
    Tyrosinase activator-1
  • HY-15257R
    Mavoglurant (Standard)

    AFQ056 (Standard)

    		 mGluR Reference Standards Neurological Disease
    Mavoglurant (Standard) is the analytical standard of Mavoglurant. This product is intended for research and analytical applications. Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mavoglurant (Standard)
  • HY-115860
    TAS-4

    		iGluR Neurological Disease
    TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .
    TAS-4
  • HY-106405R
    Nebicapone (Standard)

    BIA 3-202 (Standard)

    		 Reference Standards COMT Metabolic Disease
    Nebicapone (Standard) is the analytical standard of Nebicapone. This product is intended for research and analytical applications. Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
    Nebicapone (Standard)
  • HY-111242
    SV 156

    		Dopamine Receptor Neurological Disease
    SV 156 is a potent and selective D2 dopamine receptor antagonist, with a Ki of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype. SV 156 can be used for L-DOPA (HY-N0304)-associated abnormal involuntary movements (AIMs) research .
    SV 156

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: